Results 91 to 100 of about 41,581 (185)

A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11)

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2828-2833, August 2026.
Aim There is limited research describing rivaroxaban overdose. We aim to describe rivaroxaban overdose, coagulopathy and bleeding complications. Methods This is a prospective series of acute adult (>14 years) rivaroxaban overdose presentations >40 mg enrolled in the Australian Toxicology Monitoring study and presenting to three Australian clinical ...
Katherine Z. Isoardi   +3 more
wiley   +1 more source

Atorvastatin‐Associated Severe Bradyarrhythmia Following Multiorgan Dysfunction: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Statins are the primary treatment for hypercholesterolemia and a cornerstone of atherosclerotic cardiovascular disease prevention. Although generally safe, serious adverse effects may occur in selected patients, particularly when statins are used at high doses or without medical supervision.
Xiao‐Qing Kou   +5 more
wiley   +1 more source

Impella‐Assisted High‐Risk Percutaneous Coronary Intervention in Cardiogenic Shock With Low‐Flow, Low‐Gradient Aortic Stenosis and Multivessel Coronary Artery Disease: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Patients with cardiogenic shock, low‐flow, low‐gradient aortic stenosis, and multivessel coronary artery disease who are ineligible for surgery present a major therapeutic challenge. Percutaneous mechanical circulatory support may facilitate revascularization in this high‐risk population. A 69‐year‐old man presented after a mechanical fall and
Douni Roger   +3 more
wiley   +1 more source

Uncovering Coenzyme Q10‐Related Genetic Determinants of Statin‐Associated Muscle Symptoms: Evidence from the UK Biobank and the All of Us Research Program

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 475-483, August 2026.
Statin‐associated muscle symptoms (SAMS) are frequent adverse effects of statin therapy and have been hypothesized to result from impaired coenzyme Q10 (CoQ10) biosynthesis. Although genetic determinants of CoQ10 levels have been reported, genome‐wide association studies (GWASs) conducted specifically in statin users are lacking. Moreover, direct CoQ10
Da Hoon Lee   +6 more
wiley   +1 more source

Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 492-500, August 2026.
Coproporphyrin I (CPI) is an established endogenous biomarker for detecting drug–drug interactions (DDIs) involving the hepatic uptake transporter Organic Anion Transporting Polypeptide 1B1 (OATP1B1, gene SLCO1B1). While CPI has been extensively studied in healthy volunteers using controlled pre‐ and post‐OATP1B1‐inhibitor sampling, its applicability ...
Leila Potzel   +9 more
wiley   +1 more source

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 510-519, August 2026.
Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley   +1 more source

Dementia Risk With Combined Statin and Antihypertensive Drugs That Increase Versus Decrease Angiotensin‐II Formation: Findings From the 45 and Up Study

open access: yesInternational Journal of Geriatric Psychiatry, Volume 41, Issue 8, August 2026.
ABSTRACT Background Hypertension and dyslipidaemia are key modifiable risk factors of dementia, and the combined use of statins and antihypertensive medications (AHMs) may offer protective benefits. However, evidence on specific combinations remains limited.
Eyayaw Ashete Belachew   +3 more
wiley   +1 more source

Correlation of atorvastatin with subjective memory deficits: a study from the NHANES and FAERS databases

open access: yesFrontiers in Neurology
BackgroundPost-marketing regulatory data suggest a potential association between atorvastatin use and memory protection; however, findings from observational studies have been inconsistent and remain a subject of controversy.ObjectiveThis study aims to ...
Hao Zhang, Hua Huang, Panli Zhao
doaj   +1 more source

Atorvastatin Reduces Alcohol‐Related Cardiac and Liver Tissue Damage, Oxidative Stress, Inflammation, Apoptosis, and Thiol‐Disulfide Imbalance in Rats

open access: yesJournal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
Atorvastatin (40 mg/kg) inhibited fibrosis, hypertrophy, apoptosis, inflammation, and oxidative stress caused by alcohol consumption. It may contribute to the regulation of mitochondrial function and thiol/disulfide balance by limiting alcohol‐related heart and liver damage.
Cumaali Demirtas   +8 more
wiley   +1 more source

PHARMACOKINETIC STUDY OF ATORVASTATIN AFTER SINGLE DOSE ADMINISTRATION AMONG PAKISTANI POPULATION

open access: yesPakistan Armed Forces Medical Journal, 2017
Objective: To obtain pharmacokinetic data of Orvastin, a newly launched formulation of atorvastatin, in healthy males of Pakistan. Study Design: It was quasi-experimental design. Place and Duration of Study: Study was conducted at Centre for Research in
Imrana Maqsood,   +6 more
doaj  

Home - About - Disclaimer - Privacy